Pfizer to seek authorization for 2nd Covid booster for people 65 and older

Pfizer to seek authorization for 2nd Covid booster for people 65 and older


A medical staff prepares a booster dose of Pfizer’s coronavirus disease (COVID-19) vaccine are seen at a vaccination centre in Brussels, Belgium, January 5, 2022.

Yves Herman | Reuters

Pfizer and BioNTech are expected to seek U.S. authorization this week for a second Covid-19 vaccine booster for people 65 and older, according to a person familiar with the plans.

If the Food and Drug Administration grants authorization, the additional shot would go to a group of people who are among those with the highest risk of serious illness and death from Covid.

The FDA has authorized booster shots for everyone 12 and older on an emergency use basis.

Multiple studies have shown that the protection from the initial booster dose begins to wane after several months, particularly against the omicron variant of the coronavirus.

Pfizer CEO Albert Bourla said Friday that the company was close to submitting data to the FDA on a fourth dose of its vaccine after its scientists found that the protection from the first booster began to wane after three or four months.

The news was first reported by The Washington Post, which said that Pfizer could seek authorization as early as Tuesday.

The FDA and Pfizer did not immediately respond to requests for comment.

The Centers for Disease Control and Prevention recommends everyone ages 12 and up receive a booster five months after their second shot of either the Pfizer or the Moderna vaccine or two months after receiving the single-dose Johnson & Johnson vaccine.

More than 66 percent of Americans ages 65 and older who are eligible for a booster have received one, according to data from the CDC.

If the additional Pfizer booster is authorized, it’s unclear if every eligible person who wants a second booster will be able to get one — the U.S. government currently only has enough doses for immunocompromised people to seek a fourth shot, a senior administration official said Tuesday.

Health experts have said that additional shots will likely be needed, though it is still unclear when and how often.

Experts also still don’t know if every person will need an additional dose, but it makes sense for the elderly to get their shots first, said Dr. Anna Durbin, a vaccine researcher at Johns Hopkins University.

“Because we know already that their immune systems don’t work quite as well and that they are at higher risk for severe disease,” she said.



Source

Trump announces efforts to expand access to IVF drugs
Health

Trump announces efforts to expand access to IVF drugs

U.S. President Donald Trump delivers remarks before signing an executive order on expanding access to IVF at his Mar-a-Lago resort on Feb. 18, 2025 in Palm Beach, Florida. Joe Raedle | Getty Images President Donald Trump on Thursday announced two new efforts to expand the availability of in vitro fertilization, the first concrete step from his […]

Read More
Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers
Health

Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers

A sign is posted in front of a Genentech office on June 12, 2025 in South San Francisco, California. Justin Sullivan | Getty Images Roche‘s Genentech on Thursday said it will sell its flu pill, Xofluza, directly to certain patients at a discount in a bid to expand access, becoming the latest company to wade […]

Read More
DuPont prepares to say goodbye to electronics. What investors get with the remaining company
Health

DuPont prepares to say goodbye to electronics. What investors get with the remaining company

Earlier in the week, we looked at the upcoming DuPont electronics business spinoff and what investors are getting with the new Qnity Electronics, which has a strong foothold in the semiconductor industry. Now, here is a look at what will be left of the new DuPont after the planned Nov. 1 split and the stocks […]

Read More